

# Carlisle

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	4.5	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	4	2.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	30	19.0	158.2	(106.7-225.8)	Female	2	1.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	0	0.9	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.8	nc	(nc-nc)
Male	3	7.2	nc	(nc-nc)	<u>Ovary</u>				
Female	4	5.2	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.3	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	27	22.1	122.4	(80.6-178.1)
Female	1	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	0	1.2	nc	(nc-nc)
Male	0	2.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.6	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.8	nc	(nc-nc)
Male	0	1.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.0	nc	(nc-nc)	Female	1	3.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.1	nc	(nc-nc)	Male	52	68.2	76.3	(57.0-100.1)
Female	0	0.3	nc	(nc-nc)	Female	53	55.3	95.9	(71.8-125.4)
<u>Lung and Bronchus</u>									
Male	4	9.3	nc	(nc-nc)					
Female	3	6.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Carver

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	13.1	91.4	(47.2-159.7)	Male	8	6.8	117.9	(50.7-232.2)
Female	6	4.3	138.8	(50.7-302.0)	Female	3	5.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.4	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
Female	1	2.0	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	6	6.6	91.1	(33.3-198.4)
Female	39	45.3	86.2	(61.3-117.8)	Female	3	5.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	3	2.0	nc	(nc-nc)	Male	7	4.7	148.8	(59.6-306.7)
<u>Colon / Rectum</u>					Female	2	2.2	nc	(nc-nc)
Male	21	19.8	106.3	(65.8-162.5)	<u>Ovary</u>				
Female	21	17.8	118.3	(73.2-180.8)	Female	7	4.8	146.6	(58.7-302.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	3.2	190.3	(69.5-414.3)	Male	5	3.7	134.5	(43.3-313.9)
Female	1	0.9	nc	(nc-nc)	Female	6	3.8	159.1	(58.1-346.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.0	nc	(nc-nc)	Male	52	49.8	104.4	(78.0-137.0)
Female	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	5	3.3	149.6	(48.2-349.1)
Male	9	5.2	173.2	(79.0-328.8)	Female	4	1.8	nc	(nc-nc)
Female	8	3.2	247.8	(106.7-488.4)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.6	nc	(nc-nc)
Male	1	2.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
<u>Leukemia</u>					Female	5	4.2	118.8	(38.3-277.2)
Male	8	4.1	197.1	(84.8-388.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	3.2	nc	(nc-nc)	Female	7	9.0	77.4	(31.0-159.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.4	nc	(nc-nc)	Male	192	169.6	113.2	(97.8-130.4)
Female	1	0.9	nc	(nc-nc)	Female	160	151.3	105.8	(90.0-123.5)
<u>Lung and Bronchus</u>									
Male	23	24.5	94.0	(59.5-141.0)					
Female	24	21.0	114.2	(73.1-169.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Charlemont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.4	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	8	5.3	150.5	(64.8-296.6)	Female	0	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	1	2.1	nc	(nc-nc)	<u>Ovary</u>				
Female	3	1.9	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	5	6.1	82.5	(26.6-192.6)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.5	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.3	nc	(nc-nc)	Male	14	19.3	72.4	(39.5-121.4)
Female	0	0.1	nc	(nc-nc)	Female	16	17.0	94.0	(53.7-152.6)
<u>Lung and Bronchus</u>									
Male	3	2.7	nc	(nc-nc)					
Female	1	2.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Charlton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	8.2	85.2	(34.1-175.6)	Male	1	5.3	nc	(nc-nc)
Female	3	2.8	nc	(nc-nc)	Female	1	4.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	2.0	297.3	(108.6-647.1)	Male	1	1.3	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	3	4.9	nc	(nc-nc)
Female	37	35.2	105.0	(73.9-144.8)	Female	6	4.0	151.5	(55.3-329.7)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	2	1.9	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.7	nc	(nc-nc)
Male	13	12.9	100.7	(53.6-172.2)	<u>Ovary</u>				
Female	16	11.6	137.4	(78.5-223.2)	Female	3	3.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.2	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.9	nc	(nc-nc)	Male	39	34.5	113.0	(80.4-154.5)
Female	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	2	2.2	nc	(nc-nc)
Male	5	3.9	128.9	(41.5-300.7)	Female	1	1.3	nc	(nc-nc)
Female	4	2.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.8	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<u>Leukemia</u>					Female	2	4.2	nc	(nc-nc)
Male	3	2.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.4	nc	(nc-nc)	Female	15	6.7	222.6	(124.5-367.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	1.8	nc	(nc-nc)	Male	122	117.9	103.5	(85.9-123.5)
Female	0	0.6	nc	(nc-nc)	Female	124	110.3	112.4	(93.5-134.1)
<u>Lung and Bronchus</u>									
Male	19	15.8	120.0	(72.2-187.4)					
Female	13	13.2	98.8	(52.6-169.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chatham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	23	16.7	137.8	(87.4-206.8)	Male	14	7.1	197.8	(108.1-332.0)
Female	9	5.7	157.9	(72.1-299.8)	Female	10	4.9	204.2	(97.7-375.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	2.1	234.0	(75.4-546.1)	Male	1	2.3	nc	(nc-nc)
Female	0	1.9	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.5	nc	(nc-nc)	Male	6	7.2	83.9	(30.6-182.5)
Female	79	47.1	167.7	(132.8-209.0)	Female	8	6.7	118.6	(51.1-233.8)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	2	1.6	nc	(nc-nc)	Male	7	4.8	144.4	(57.8-297.5)
<u>Colon / Rectum</u>					Female	3	2.6	nc	(nc-nc)
Male	20	24.2	82.6	(50.4-127.5)	<u>Ovary</u>				
Female	25	23.8	105.0	(67.9-155.0)	Female	9	5.2	174.2	(79.5-330.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	3.7	187.6	(75.2-386.6)	Male	7	4.5	153.9	(61.7-317.1)
Female	1	1.1	nc	(nc-nc)	Female	6	5.1	117.9	(43.1-256.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	77	60.7	126.8	(100.0-158.5)
Female	1	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	2	4.1	nc	(nc-nc)
Male	12	5.7	210.4	(108.6-367.6)	Female	1	2.6	nc	(nc-nc)
Female	3	3.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.8	nc	(nc-nc)
Male	4	2.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	3	2.8	nc	(nc-nc)
Male	3	4.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	3.7	nc	(nc-nc)	Female	13	9.8	132.2	(70.3-226.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.6	nc	(nc-nc)	Male	225	199.7	112.6	(98.4-128.4)
Female	0	1.1	nc	(nc-nc)	Female	212	172.4	122.9	(107.0-140.7)
<u>Lung and Bronchus</u>									
Male	18	30.2	59.5	(35.3-94.1)					
Female	17	25.9	65.7	(38.3-105.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chelmsford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	23	34.6	66.5	(42.1-99.8)	Male	19	19.6	96.9	(58.3-151.3)
Female	18	13.3	135.0	(79.9-213.3)	Female	10	16.8	59.7	(28.6-109.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	7.0	85.4	(31.2-185.9)	Male	4	5.1	nc	(nc-nc)
Female	2	6.3	nc	(nc-nc)	Female	2	4.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	22	18.4	119.4	(74.8-180.8)
Female	148	146.3	101.2	(85.5-118.9)	Female	22	17.5	125.5	(78.6-189.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	6.5	nc	(nc-nc)	Male	11	14.3	77.0	(38.4-137.8)
<b><u>Colon / Rectum</u></b>					Female	6	7.2	83.7	(30.6-182.3)
Male	56	53.2	105.3	(79.6-136.8)	<b><u>Ovary</u></b>				
Female	55	54.2	101.5	(76.4-132.1)	Female	12	15.3	78.6	(40.6-137.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	8	9.1	88.4	(38.0-174.1)	Male	10	10.1	98.9	(47.4-181.9)
Female	3	2.6	nc	(nc-nc)	Female	10	11.4	87.6	(41.9-161.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	2.9	nc	(nc-nc)	Male	167	150.2	111.2	(95.0-129.4)
Female	4	2.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	8.9	nc	(nc-nc)
Male	19	15.3	124.1	(74.7-193.8)	Female	3	5.6	nc	(nc-nc)
Female	10	10.1	99.4	(47.6-182.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	5.3	94.7	(30.5-221.0)
Male	5	6.4	77.7	(25.1-181.4)	<b><u>Thyroid</u></b>				
Female	1	1.9	nc	(nc-nc)	Male	8	4.1	194.1	(83.6-382.5)
<b><u>Leukemia</u></b>					Female	20	13.6	147.2	(89.9-227.4)
Male	12	11.1	107.7	(55.6-188.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	10	9.7	103.0	(49.3-189.4)	Female	30	30.1	99.7	(67.3-142.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	12	7.1	168.6	(87.0-294.5)	Male	492	483.0	101.9	(93.1-111.3)
Female	2	2.7	nc	(nc-nc)	Female	455	476.9	95.4	(86.8-104.6)
<b><u>Lung and Bronchus</u></b>									
Male	67	67.8	98.8	(76.6-125.5)					
Female	55	64.7	85.0	(64.0-110.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chelsea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	34	31.0	109.7	(75.9-153.3)	Male	5	16.9	29.6	(9.5-69.1)
Female	11	10.6	104.1	(51.9-186.3)	Female	12	13.5	88.6	(45.7-154.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	6.4	110.2	(44.1-227.0)	Male	10	4.5	224.2	(107.3-412.4)
Female	9	5.3	169.9	(77.5-322.5)	Female	0	3.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	19	16.3	116.2	(70.0-181.5)
Female	82	106.6	76.9	(61.2-95.4)	Female	17	14.0	121.2	(70.5-194.0)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	14	5.2	269.6	(147.3-452.4)	Male	18	11.2	160.9	(95.3-254.4)
<u>Colon / Rectum</u>					Female	0	5.5	nc	(nc-nc)
Male	45	46.6	96.5	(70.4-129.1)	<u>Ovary</u>				
Female	48	44.1	108.8	(80.2-144.3)	Female	12	11.5	104.0	(53.7-181.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	17	7.5	227.8	(132.6-364.7)	Male	12	8.7	137.2	(70.8-239.7)
Female	2	2.1	nc	(nc-nc)	Female	7	9.3	75.6	(30.3-155.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	3.1	nc	(nc-nc)	Male	85	119.1	71.4	(57.0-88.3)
Female	1	2.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	10	8.0	125.4	(60.1-230.7)
Male	19	12.4	152.7	(91.9-238.6)	Female	5	4.8	104.6	(33.7-244.0)
Female	10	7.7	130.2	(62.3-239.5)	<u>Testis</u>				
<u>Larynx</u>					Male	2	6.1	nc	(nc-nc)
Male	15	5.2	291.2	(162.8-480.3)	<u>Thyroid</u>				
Female	3	1.3	nc	(nc-nc)	Male	4	3.6	nc	(nc-nc)
<u>Leukemia</u>					Female	10	11.6	86.1	(41.2-158.3)
Male	8	10.3	77.7	(33.5-153.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	8.3	95.9	(41.3-189.0)	Female	25	21.2	117.8	(76.2-173.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	10	5.7	174.2	(83.4-320.4)	Male	422	409.8	103.0	(93.4-113.3)
Female	3	2.2	nc	(nc-nc)	Female	363	368.3	98.6	(88.7-109.2)
<u>Lung and Bronchus</u>									
Male	66	57.6	114.6	(88.6-145.8)					
Female	51	49.0	104.2	(77.6-137.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Cheshire

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	4.4	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	3	1.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	0.8	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	2	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	2.3	nc	(nc-nc)
Female	13	14.4	90.6	(48.2-154.9)	Female	1	1.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	0	0.6	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.7	nc	(nc-nc)
Male	6	6.8	88.8	(32.4-193.3)	<u>Ovary</u>				
Female	5	5.1	97.5	(31.4-227.6)	Female	0	1.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	1.1	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	4	1.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.3	nc	(nc-nc)	Male	16	18.5	86.5	(49.4-140.6)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	1	1.1	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.5	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.2	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.3	nc	(nc-nc)
Male	3	1.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.9	nc	(nc-nc)	Female	2	2.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.9	nc	(nc-nc)	Male	56	59.8	93.7	(70.8-121.7)
Female	0	0.3	nc	(nc-nc)	Female	49	46.2	106.0	(78.4-140.2)
<u>Lung and Bronchus</u>									
Male	10	8.5	117.4	(56.2-215.9)					
Female	11	6.3	174.9	(87.2-313.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.4	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	7	5.0	139.7	(56.0-287.9)	Female	1	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.2	nc	(nc-nc)
Male	2	2.2	nc	(nc-nc)	<u>Ovary</u>				
Female	1	1.7	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	8	5.9	135.6	(58.4-267.2)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.5	nc	(nc-nc)
Male	2	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.3	nc	(nc-nc)	Male	22	19.4	113.3	(71.0-171.6)
Female	0	0.1	nc	(nc-nc)	Female	19	15.9	119.4	(71.8-186.4)
<u>Lung and Bronchus</u>									
Male	3	2.7	nc	(nc-nc)					
Female	1	2.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chesterfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.2	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	4	4.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	0	1.8	nc	(nc-nc)	<u>Ovary</u>				
Female	1	1.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	5.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.5	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.3	nc	(nc-nc)	Male	8	16.5	48.5	(20.9-95.5)
Female	0	0.1	nc	(nc-nc)	Female	12	13.5	89.2	(46.0-155.7)
<u>Lung and Bronchus</u>									
Male	1	2.3	nc	(nc-nc)					
Female	3	1.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chicopee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	69	68.8	100.3	(78.1-127.0)	Male	30	34.5	86.9	(58.6-124.0)
Female	28	26.5	105.8	(70.3-152.9)	Female	21	28.6	73.4	(45.4-112.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	14	11.9	118.1	(64.5-198.2)	Male	10	9.8	102.2	(48.9-188.0)
Female	13	11.1	116.7	(62.1-199.6)	Female	12	8.7	138.5	(71.5-242.0)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	2.1	nc	(nc-nc)	Male	31	33.7	92.0	(62.5-130.6)
Female	250	251.6	99.3	(87.4-112.5)	Female	24	33.6	71.5	(45.8-106.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	10	10.4	96.5	(46.2-177.4)	Male	19	23.9	79.5	(47.9-124.2)
<b><u>Colon / Rectum</u></b>					Female	12	13.0	92.3	(47.7-161.3)
Male	92	102.8	89.5	(72.2-109.8)	<b><u>Ovary</u></b>				
Female	116	109.1	106.3	(87.9-127.5)	Female	26	27.0	96.1	(62.8-140.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	20	16.5	121.5	(74.2-187.7)	Male	10	19.4	51.7	(24.7-95.0)
Female	4	5.2	nc	(nc-nc)	Female	22	23.3	94.5	(59.2-143.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	4.9	nc	(nc-nc)	Male	267	266.3	100.3	(88.6-113.0)
Female	3	4.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	22	17.3	127.4	(79.8-193.0)
Male	24	26.9	89.4	(57.2-133.0)	Female	14	11.5	122.3	(66.8-205.1)
Female	16	18.7	85.3	(48.8-138.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	7	8.2	85.3	(34.2-175.8)
Male	9	11.4	79.1	(36.1-150.1)	<b><u>Thyroid</u></b>				
Female	4	3.3	nc	(nc-nc)	Male	1	6.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	13	21.2	61.3	(32.6-104.8)
Male	20	20.7	96.6	(59.0-149.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	10	18.5	54.2	(25.9-99.6)	Female	63	51.3	122.7	(94.3-157.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	12	12.4	96.7	(49.9-169.0)	Male	849	887.3	95.7	(89.4-102.3)
Female	5	5.3	95.1	(30.6-221.9)	Female	853	874.8	97.5	(91.1-104.3)
<b><u>Lung and Bronchus</u></b>									
Male	122	129.4	94.3	(78.3-112.6)					
Female	111	125.6	88.4	(72.7-106.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chilmark

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.4	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	6	4.2	141.7	(51.8-308.5)	Female	1	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	1	2.0	nc	(nc-nc)	<u>Ovary</u>				
Female	1	1.6	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	7	5.4	129.0	(51.7-265.7)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	0	0.3	nc	(nc-nc)
Male	2	0.5	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.4	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.3	nc	(nc-nc)	Male	16	17.6	90.8	(51.9-147.5)
Female	0	0.1	nc	(nc-nc)	Female	14	13.8	101.1	(55.2-169.7)
<u>Lung and Bronchus</u>									
Male	2	2.5	nc	(nc-nc)					
Female	3	1.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Clarksburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	2.2	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	3	7.8	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	2	3.3	nc	(nc-nc)	<u>Ovary</u>				
Female	3	3.0	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.6	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.2	nc	(nc-nc)	Male	7	9.7	72.5	(29.0-149.3)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	0	0.6	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.3	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.7	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	3	1.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	26	30.1	86.3	(56.4-126.4)
Female	0	0.1	nc	(nc-nc)	Female	21	25.8	81.5	(50.5-124.6)
<u>Lung and Bronchus</u>									
Male	6	4.3	138.4	(50.5-301.2)					
Female	5	3.6	138.3	(44.6-322.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Clinton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	14.2	91.6	(48.7-156.6)	Male	3	7.6	nc	(nc-nc)
Female	4	5.8	nc	(nc-nc)	Female	7	6.6	105.4	(42.2-217.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.7	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
Female	2	2.6	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	7	7.3	95.9	(38.4-197.6)
Female	47	56.4	83.3	(61.2-110.8)	Female	5	7.5	67.0	(21.6-156.4)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	6	2.5	243.0	(88.7-528.9)	Male	8	5.2	154.1	(66.4-303.7)
<u>Colon / Rectum</u>					Female	1	2.9	nc	(nc-nc)
Male	19	21.4	88.9	(53.5-138.8)	<u>Ovary</u>				
Female	23	24.2	95.2	(60.3-142.8)	Female	11	6.1	181.7	(90.6-325.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	3.5	173.6	(63.4-377.9)	Male	2	4.0	nc	(nc-nc)
Female	3	1.1	nc	(nc-nc)	Female	4	5.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.2	nc	(nc-nc)	Male	46	55.5	82.9	(60.7-110.5)
Female	1	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	4	3.6	nc	(nc-nc)
Male	3	5.8	nc	(nc-nc)	Female	0	2.6	nc	(nc-nc)
Female	9	4.1	218.2	(99.6-414.2)	<u>Testis</u>				
<u>Larynx</u>					Male	0	2.2	nc	(nc-nc)
Male	3	2.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<u>Leukemia</u>					Female	4	5.2	nc	(nc-nc)
Male	1	4.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	4.2	nc	(nc-nc)	Female	6	11.3	53.1	(19.4-115.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	2.7	nc	(nc-nc)	Male	172	187.3	91.8	(78.6-106.6)
Female	0	1.2	nc	(nc-nc)	Female	173	195.0	88.7	(76.0-102.9)
<u>Lung and Bronchus</u>									
Male	33	26.8	123.2	(84.8-173.0)					
Female	20	27.1	73.7	(45.0-113.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Cohasset

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	8.6	139.2	(71.8-243.1)	Male	7	4.6	151.7	(60.8-312.5)
Female	3	3.2	nc	(nc-nc)	Female	16	3.7	430.3	(245.8-698.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.6	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	4.4	113.8	(36.7-265.6)
Female	36	33.4	107.9	(75.6-149.4)	Female	3	4.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	2	1.4	nc	(nc-nc)	Male	6	3.4	177.0	(64.6-385.3)
<u>Colon / Rectum</u>					Female	2	1.6	nc	(nc-nc)
Male	19	13.2	144.4	(86.9-225.5)	<u>Ovary</u>				
Female	11	12.9	85.5	(42.6-153.0)	Female	4	3.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.2	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	2.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	38	36.1	105.3	(74.5-144.5)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	1	2.2	nc	(nc-nc)
Male	4	3.7	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
Female	1	2.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.0	nc	(nc-nc)
Male	0	1.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	3	0.9	nc	(nc-nc)
<u>Leukemia</u>					Female	4	2.9	nc	(nc-nc)
Male	5	2.7	186.5	(60.1-435.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	2.3	nc	(nc-nc)	Female	5	6.8	73.3	(23.6-171.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.7	nc	(nc-nc)	Male	133	116.7	114.0	(95.4-135.1)
Female	3	0.6	nc	(nc-nc)	Female	108	110.0	98.2	(80.5-118.5)
<u>Lung and Bronchus</u>									
Male	12	16.6	72.1	(37.2-126.0)					
Female	7	15.2	46.0	(18.4-94.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Colrain

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	8	6.7	119.7	(51.5-235.8)	Female	0	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.3	nc	(nc-nc)
Male	2	3.2	nc	(nc-nc)	<u>Ovary</u>				
Female	3	2.3	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	3	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	8.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	0	0.5	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.7	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.4	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.4	nc	(nc-nc)	Male	18	27.8	64.8	(38.4-102.4)
Female	0	0.1	nc	(nc-nc)	Female	28	21.3	131.7	(87.5-190.3)
<u>Lung and Bronchus</u>									
Male	4	4.0	nc	(nc-nc)					
Female	6	2.8	210.8	(77.0-458.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Concord

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	23.1	77.9	(46.2-123.2)	Male	24	12.1	198.4	(127.1-295.2)
Female	10	7.7	129.6	(62.0-238.3)	Female	19	8.7	218.1	(131.2-340.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	4.1	nc	(nc-nc)	Male	6	3.3	179.3	(65.5-390.3)
Female	4	3.4	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.7	nc	(nc-nc)	Male	14	11.6	120.9	(66.0-202.8)
Female	104	80.1	129.9	(106.1-157.4)	Female	13	9.8	132.2	(70.3-226.1)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	4	3.2	nc	(nc-nc)	Male	9	8.7	103.4	(47.2-196.2)
<u>Colon / Rectum</u>					Female	7	4.0	176.0	(70.5-362.6)
Male	27	34.9	77.3	(51.0-112.5)	<u>Ovary</u>				
Female	30	31.9	94.2	(63.5-134.4)	Female	5	8.4	59.3	(19.1-138.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	5.8	nc	(nc-nc)	Male	3	6.6	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	10	6.7	149.0	(71.3-274.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	1.6	nc	(nc-nc)	Male	103	93.8	109.8	(89.6-133.2)
Female	1	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	2	5.9	nc	(nc-nc)
Male	5	9.5	52.8	(17.0-123.3)	Female	3	3.4	nc	(nc-nc)
Female	10	5.6	178.0	(85.2-327.4)	<u>Testis</u>				
<u>Larynx</u>					Male	5	2.7	187.1	(60.3-436.6)
Male	3	4.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.0	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
<u>Leukemia</u>					Female	5	6.5	77.2	(24.9-180.1)
Male	7	7.0	100.1	(40.1-206.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	5.5	nc	(nc-nc)	Female	20	16.4	121.7	(74.3-187.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	4.4	nc	(nc-nc)	Male	280	306.4	91.4	(81.0-102.7)
Female	4	1.6	nc	(nc-nc)	Female	289	265.5	108.9	(96.7-122.2)
<u>Lung and Bronchus</u>									
Male	23	43.9	52.4	(33.2-78.6)					
Female	23	36.6	62.9	(39.9-94.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Conway

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.7	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	4	7.1	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.3	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.3	nc	(nc-nc)
Male	2	2.7	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	4	2.2	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	9	7.6	119.1	(54.3-226.0)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.5	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.3	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.7	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.4	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	20	24.7	80.8	(49.3-124.8)
Female	0	0.1	nc	(nc-nc)	Female	17	21.7	78.5	(45.7-125.6)
<b><u>Lung and Bronchus</u></b>									
Male	0	3.4	nc	(nc-nc)					
Female	2	2.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Cummington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	0.9	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	3	3.7	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.2	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<u>Ovary</u>				
Female	1	1.3	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	4.0	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	2	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.4	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.2	nc	(nc-nc)	Male	10	13.2	75.8	(36.3-139.4)
Female	0	0.1	nc	(nc-nc)	Female	12	11.9	100.8	(52.0-176.1)
<u>Lung and Bronchus</u>									
Male	1	1.9	nc	(nc-nc)					
Female	2	1.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dalton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	8.1	123.1	(58.9-226.4)	Male	11	4.3	258.6	(128.9-462.8)
Female	3	3.2	nc	(nc-nc)	Female	2	3.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.5	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	6	4.1	146.4	(53.4-318.6)
Female	30	32.3	92.9	(62.7-132.7)	Female	3	4.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	1	1.3	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.6	nc	(nc-nc)
Male	13	12.3	105.8	(56.3-180.9)	<u>Ovary</u>				
Female	18	13.4	134.2	(79.5-212.1)	Female	3	3.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.0	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.6	nc	(nc-nc)	Male	40	32.6	122.6	(87.6-166.9)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	2	2.1	nc	(nc-nc)
Male	5	3.3	150.8	(48.6-351.9)	Female	0	1.4	nc	(nc-nc)
Female	4	2.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.0	nc	(nc-nc)
Male	2	1.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Leukemia</u>					Female	2	2.7	nc	(nc-nc)
Male	3	2.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	2.3	nc	(nc-nc)	Female	5	6.5	76.5	(24.7-178.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.6	nc	(nc-nc)	Male	123	107.5	114.4	(95.1-136.5)
Female	0	0.6	nc	(nc-nc)	Female	103	109.5	94.1	(76.8-114.1)
<u>Lung and Bronchus</u>									
Male	15	15.5	97.0	(54.3-160.0)					
Female	18	15.3	117.4	(69.6-185.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Danvers

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	42	31.0	135.7	(97.8-183.4)	Male	19	16.0	118.7	(71.5-185.4)
Female	11	12.0	91.6	(45.7-164.0)	Female	9	13.5	66.8	(30.5-126.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.5	109.5	(40.0-238.3)	Male	3	4.5	nc	(nc-nc)
Female	6	5.2	115.8	(42.3-252.0)	Female	2	3.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.0	nc	(nc-nc)	Male	19	15.4	123.2	(74.2-192.5)
Female	127	119.2	106.6	(88.8-126.8)	Female	14	15.3	91.5	(50.0-153.5)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	5	5.0	99.6	(32.1-232.4)	Male	4	11.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	7	6.0	115.9	(46.4-238.9)
Male	68	46.6	146.0	(113.3-185.1)	<u>Ovary</u>				
Female	45	49.6	90.7	(66.1-121.4)	Female	17	12.7	134.1	(78.0-214.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	7.6	92.0	(36.9-189.6)	Male	11	8.8	125.1	(62.4-223.8)
Female	4	2.4	nc	(nc-nc)	Female	8	10.5	76.2	(32.8-150.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.2	nc	(nc-nc)	Male	116	124.3	93.4	(77.1-112.0)
Female	3	2.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	7	7.8	89.4	(35.8-184.2)
Male	16	12.5	128.1	(73.2-208.0)	Female	3	5.3	nc	(nc-nc)
Female	7	8.6	81.5	(32.7-168.0)	<u>Testis</u>				
<u>Larynx</u>					Male	4	3.7	nc	(nc-nc)
Male	0	5.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.5	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
<u>Leukemia</u>					Female	8	10.3	77.9	(33.5-153.5)
Male	13	9.4	138.8	(73.9-237.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	10	8.5	117.8	(56.4-216.6)	Female	16	24.1	66.3	(37.9-107.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	5.8	103.3	(37.7-224.8)	Male	443	407.5	108.7	(98.8-119.3)
Female	1	2.4	nc	(nc-nc)	Female	416	405.2	102.7	(93.0-113.0)
<u>Lung and Bronchus</u>									
Male	65	58.8	110.6	(85.3-140.9)					
Female	73	56.5	129.2	(101.3-162.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dartmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	35	36.5	95.9	(66.8-133.3)	Male	14	19.1	73.2	(40.0-122.8)
Female	17	13.3	127.7	(74.4-204.5)	Female	17	15.1	112.6	(65.5-180.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	6.6	105.4	(42.2-217.1)	Male	7	5.3	132.7	(53.2-273.4)
Female	6	5.8	103.5	(37.8-225.3)	Female	10	4.4	229.4	(109.8-422.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.1	nc	(nc-nc)	Male	15	18.5	81.2	(45.4-133.9)
Female	115	133.2	86.4	(71.3-103.7)	Female	17	17.1	99.6	(58.0-159.4)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	7	5.5	126.9	(50.8-261.4)	Male	20	13.6	147.5	(90.1-227.9)
<u>Colon / Rectum</u>					Female	4	6.8	nc	(nc-nc)
Male	77	55.2	139.6	(110.1-174.5)	<u>Ovary</u>				
Female	42	54.9	76.4	(55.1-103.3)	Female	11	14.2	77.4	(38.6-138.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	9.0	nc	(nc-nc)	Male	13	10.4	124.7	(66.3-213.2)
Female	1	2.6	nc	(nc-nc)	Female	14	11.6	120.2	(65.6-201.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	3.0	nc	(nc-nc)	Male	178	145.9	122.0	(104.7-141.3)
Female	2	2.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	11	9.3	118.4	(59.0-211.9)
Male	27	14.8	182.4	(120.2-265.4)	Female	10	5.8	173.3	(83.0-318.8)
Female	10	9.6	104.1	(49.9-191.5)	<u>Testis</u>				
<u>Larynx</u>					Male	3	4.8	nc	(nc-nc)
Male	7	6.3	111.6	(44.7-230.0)	<u>Thyroid</u>				
Female	2	1.7	nc	(nc-nc)	Male	1	3.7	nc	(nc-nc)
<u>Leukemia</u>					Female	10	11.5	87.2	(41.7-160.3)
Male	10	11.2	89.2	(42.7-164.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	9.4	74.5	(29.8-153.5)	Female	26	27.2	95.8	(62.5-140.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	6.9	72.5	(23.4-169.1)	Male	524	482.8	108.5	(99.4-118.2)
Female	2	2.7	nc	(nc-nc)	Female	420	452.0	92.9	(84.2-102.2)
<u>Lung and Bronchus</u>									
Male	63	69.1	91.1	(70.0-116.6)					
Female	54	63.3	85.4	(64.1-111.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dedham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	32	29.6	108.1	(73.9-152.6)	Male	14	15.2	92.1	(50.3-154.6)
Female	11	10.8	102.0	(50.8-182.4)	Female	13	12.2	106.4	(56.6-181.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	5.2	nc	(nc-nc)	Male	7	4.2	165.4	(66.2-340.7)
Female	2	4.7	nc	(nc-nc)	Female	4	3.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.9	nc	(nc-nc)	Male	15	14.7	102.2	(57.1-168.5)
Female	124	107.3	115.5	(96.1-137.8)	Female	10	13.8	72.6	(34.8-133.5)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	3	4.5	nc	(nc-nc)	Male	13	10.6	122.8	(65.3-210.1)
<u>Colon / Rectum</u>					Female	1	5.5	nc	(nc-nc)
Male	43	44.4	96.9	(70.1-130.5)	<u>Ovary</u>				
Female	43	44.1	97.5	(70.5-131.3)	Female	14	11.4	122.8	(67.1-206.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	7.2	69.6	(22.4-162.5)	Male	9	8.4	107.6	(49.1-204.3)
Female	2	2.1	nc	(nc-nc)	Female	11	9.4	117.2	(58.4-209.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	2.1	nc	(nc-nc)	Male	124	116.7	106.3	(88.4-126.7)
Female	3	1.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	8	7.5	107.1	(46.1-211.0)
Male	15	11.8	127.4	(71.2-210.1)	Female	2	4.6	nc	(nc-nc)
Female	10	7.8	128.6	(61.6-236.5)	<u>Testis</u>				
<u>Larynx</u>					Male	7	3.7	187.0	(74.9-385.3)
Male	3	5.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.4	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
<u>Leukemia</u>					Female	9	9.3	96.8	(44.2-183.7)
Male	7	9.0	78.1	(31.3-161.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	7.6	105.1	(45.3-207.2)	Female	23	22.0	104.6	(66.3-157.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	5.5	128.3	(51.4-264.3)	Male	406	386.3	105.1	(95.1-115.8)
Female	3	2.1	nc	(nc-nc)	Female	386	364.8	105.8	(95.5-116.9)
<u>Lung and Bronchus</u>									
Male	51	55.9	91.3	(68.0-120.1)					
Female	65	51.5	126.3	(97.5-161.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Deerfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	5.6	nc	(nc-nc)	Male	7	3.1	224.8	(90.1-463.3)
Female	5	1.9	257.1	(82.9-600.1)	Female	2	2.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.1	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
Female	16	21.5	74.3	(42.5-120.7)	Female	2	2.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	1	0.9	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.0	nc	(nc-nc)
Male	6	8.7	69.1	(25.2-150.5)	<u>Ovary</u>				
Female	7	8.0	87.9	(35.2-181.1)	Female	1	2.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.4	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	21	23.2	90.5	(56.0-138.4)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	0	1.5	nc	(nc-nc)
Male	2	2.4	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.7	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	1	2.0	nc	(nc-nc)
Male	4	1.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.4	nc	(nc-nc)	Female	3	4.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.1	nc	(nc-nc)	Male	65	76.6	84.9	(65.5-108.2)
Female	0	0.4	nc	(nc-nc)	Female	47	69.8	67.4	(49.5-89.6)
<u>Lung and Bronchus</u>									
Male	5	10.8	46.2	(14.9-107.7)					
Female	5	9.5	52.8	(17.0-123.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dennis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	36	33.1	108.8	(76.2-150.6)	Male	30	14.6	205.4	(138.6-293.3)
Female	16	11.1	143.6	(82.0-233.1)	Female	20	10.6	188.7	(115.2-291.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	4.5	nc	(nc-nc)	Male	4	4.6	nc	(nc-nc)
Female	4	4.1	nc	(nc-nc)	Female	4	3.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.0	nc	(nc-nc)	Male	18	14.6	123.4	(73.1-195.1)
Female	113	100.3	112.6	(92.8-135.4)	Female	16	13.6	117.5	(67.1-190.8)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	5	3.6	138.0	(44.5-322.1)	Male	12	10.2	117.9	(60.9-206.0)
<u>Colon / Rectum</u>					Female	8	5.3	152.2	(65.5-299.9)
Male	42	48.4	86.8	(62.6-117.4)	<u>Ovary</u>				
Female	46	45.4	101.4	(74.2-135.2)	Female	19	10.8	175.8	(105.8-274.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	7.6	105.0	(45.2-206.9)	Male	8	9.1	87.8	(37.8-173.1)
Female	3	2.2	nc	(nc-nc)	Female	9	9.8	92.2	(42.1-175.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.5	nc	(nc-nc)	Male	173	126.2	137.1	(117.4-159.1)
Female	1	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	3	8.1	nc	(nc-nc)
Male	12	11.9	101.1	(52.2-176.6)	Female	3	4.7	nc	(nc-nc)
Female	8	7.7	103.9	(44.7-204.7)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.9	nc	(nc-nc)
Male	2	5.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.4	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
<u>Leukemia</u>					Female	6	6.8	87.9	(32.1-191.3)
Male	9	9.0	100.2	(45.7-190.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	7.2	97.2	(38.9-200.3)	Female	21	21.1	99.4	(61.5-151.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	5.4	92.0	(29.6-214.7)	Male	449	408.0	110.1	(100.1-120.7)
Female	1	2.2	nc	(nc-nc)	Female	394	353.3	111.5	(100.8-123.1)
<u>Lung and Bronchus</u>									
Male	48	61.5	78.1	(57.6-103.6)					
Female	58	53.3	108.9	(82.7-140.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dighton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	6.6	106.7	(42.8-219.9)	Male	0	3.6	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	1.3	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	11	3.5	318.8	(158.9-570.5)
Female	31	25.0	124.2	(84.4-176.3)	Female	3	3.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	1	1.1	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.2	nc	(nc-nc)
Male	16	10.0	159.4	(91.0-258.8)	<u>Ovary</u>				
Female	8	9.5	84.7	(36.4-166.8)	Female	1	2.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.7	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.5	nc	(nc-nc)	Male	29	26.9	107.7	(72.1-154.7)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	0	1.7	nc	(nc-nc)
Male	2	2.8	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Female	3	1.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.0	nc	(nc-nc)
Male	2	1.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	5	2.4	210.3	(67.8-490.8)
Male	3	2.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.7	nc	(nc-nc)	Female	2	5.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.3	nc	(nc-nc)	Male	103	89.0	115.7	(94.4-140.3)
Female	2	0.5	nc	(nc-nc)	Female	87	82.1	106.0	(84.9-130.8)
<u>Lung and Bronchus</u>									
Male	15	12.5	119.5	(66.9-197.2)					
Female	12	11.1	108.2	(55.9-189.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Douglas

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	4.9	nc	(nc-nc)	Male	4	3.2	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	Female	1	2.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.2	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	3.0	nc	(nc-nc)
Female	27	20.9	129.2	(85.1-188.0)	Female	1	2.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	1	1.1	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.0	nc	(nc-nc)
Male	7	7.7	90.6	(36.3-186.6)	<u>Ovary</u>				
Female	6	7.1	84.9	(31.0-184.8)	Female	1	2.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.3	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
Female	2	0.3	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	15	19.9	75.3	(42.1-124.2)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	3	1.3	nc	(nc-nc)
Male	0	2.3	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.2	nc	(nc-nc)
Male	2	0.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	2	2.5	nc	(nc-nc)
Male	1	1.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.4	nc	(nc-nc)	Female	5	4.0	125.0	(40.3-291.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.1	nc	(nc-nc)	Male	60	70.0	85.7	(65.4-110.4)
Female	0	0.4	nc	(nc-nc)	Female	64	66.4	96.3	(74.2-123.0)
<u>Lung and Bronchus</u>									
Male	6	9.4	64.0	(23.4-139.3)					
Female	8	8.1	98.2	(42.3-193.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	6.2	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
Female	0	1.8	nc	(nc-nc)	Female	7	2.5	276.6	(110.8-569.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.2	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	3	1.0	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	3.3	nc	(nc-nc)
Female	22	22.8	96.4	(60.4-145.9)	Female	3	2.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	0	1.0	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.1	nc	(nc-nc)
Male	10	9.6	103.9	(49.8-191.1)	<u>Ovary</u>				
Female	8	7.2	110.9	(47.7-218.4)	Female	6	2.3	258.2	(94.3-562.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.6	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	39	27.2	143.6	(102.1-196.3)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	5	1.6	312.8	(100.8-729.9)
Male	1	2.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.7	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	4	2.1	nc	(nc-nc)
Male	1	2.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.4	nc	(nc-nc)	Female	4	4.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.3	nc	(nc-nc)	Male	80	86.7	92.3	(73.2-114.9)
Female	0	0.4	nc	(nc-nc)	Female	76	70.4	108.0	(85.1-135.2)
<u>Lung and Bronchus</u>									
Male	5	12.2	40.9	(13.2-95.5)					
Female	9	9.4	96.0	(43.8-182.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dracut

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	28	25.9	108.3	(72.0-156.5)	Male	3	15.0	nc	(nc-nc)
Female	12	9.5	127.0	(65.5-221.8)	Female	12	12.8	93.8	(48.4-163.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	5.5	126.9	(50.9-261.6)	Male	3	3.8	nc	(nc-nc)
Female	3	4.8	nc	(nc-nc)	Female	6	3.1	193.5	(70.6-421.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	10	14.1	70.7	(33.9-130.1)
Female	105	106.4	98.7	(80.7-119.5)	Female	15	12.8	117.2	(65.6-193.4)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	4	5.0	nc	(nc-nc)	Male	11	10.6	104.2	(51.9-186.4)
<u>Colon / Rectum</u>					Female	7	5.2	135.2	(54.2-278.6)
Male	35	39.7	88.1	(61.3-122.5)	<u>Ovary</u>				
Female	54	37.9	142.3	(106.9-185.7)	Female	17	11.1	153.4	(89.3-245.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	6.7	134.9	(61.6-256.2)	Male	6	7.5	79.9	(29.2-173.9)
Female	4	1.8	nc	(nc-nc)	Female	9	8.1	111.6	(50.9-211.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.5	nc	(nc-nc)	Male	114	109.1	104.5	(86.2-125.5)
Female	2	2.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	6	6.6	90.6	(33.1-197.2)
Male	13	11.4	113.7	(60.5-194.4)	Female	4	3.9	nc	(nc-nc)
Female	7	7.3	95.4	(38.2-196.6)	<u>Testis</u>				
<u>Larynx</u>					Male	6	4.7	126.6	(46.2-275.6)
Male	7	4.7	148.2	(59.4-305.4)	<u>Thyroid</u>				
Female	3	1.3	nc	(nc-nc)	Male	5	3.3	153.1	(49.4-357.4)
<u>Leukemia</u>					Female	9	11.0	82.1	(37.5-155.9)
Male	8	8.6	92.8	(40.0-182.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	7.1	nc	(nc-nc)	Female	30	21.4	140.2	(94.6-200.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	5.3	nc	(nc-nc)	Male	359	360.4	99.6	(89.6-110.5)
Female	2	1.9	nc	(nc-nc)	Female	391	345.9	113.0	(102.1-124.8)
<u>Lung and Bronchus</u>									
Male	63	50.6	124.5	(95.7-159.3)					
Female	52	47.0	110.6	(82.6-145.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

## Dudley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	10.4	86.4	(39.4-164.0)	Male	3	5.6	nc	(nc-nc)
Female	3	3.6	nc	(nc-nc)	Female	7	4.5	156.2	(62.6-321.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.0	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	3	5.4	nc	(nc-nc)
Female	33	38.0	86.9	(59.8-122.0)	Female	5	4.7	105.3	(33.9-245.8)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	0	1.7	nc	(nc-nc)	Male	3	4.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.9	nc	(nc-nc)
Male	14	15.8	88.6	(48.4-148.7)	<u>Ovary</u>				
Female	13	14.7	88.4	(47.0-151.2)	Female	9	4.0	223.6	(102.0-424.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.6	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	3	3.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.9	nc	(nc-nc)	Male	33	41.6	79.3	(54.6-111.4)
Female	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	2	2.7	nc	(nc-nc)
Male	2	4.3	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
Female	1	2.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.6	nc	(nc-nc)
Male	1	1.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	0.5	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<u>Leukemia</u>					Female	3	3.7	nc	(nc-nc)
Male	3	3.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	2.6	nc	(nc-nc)	Female	9	7.6	117.8	(53.7-223.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.0	nc	(nc-nc)	Male	106	139.3	76.1	(62.3-92.1)
Female	0	0.7	nc	(nc-nc)	Female	116	126.5	91.7	(75.7-109.9)
<u>Lung and Bronchus</u>									
Male	12	19.7	60.8	(31.4-106.2)					
Female	15	17.3	86.9	(48.6-143.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dunstable

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	2.1	nc	(nc-nc)	Male	4	1.4	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	2	0.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
Female	9	9.5	94.6	(43.2-179.7)	Female	0	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	0.4	nc	(nc-nc)
Male	0	3.4	nc	(nc-nc)	<u>Ovary</u>				
Female	3	2.6	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.2	nc	(nc-nc)	Male	12	9.9	121.3	(62.6-211.9)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	1	0.6	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.1	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.6	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.5	nc	(nc-nc)	Male	32	32.0	99.9	(68.3-141.0)
Female	0	0.1	nc	(nc-nc)	Female	28	28.0	100.1	(66.5-144.6)
<u>Lung and Bronchus</u>									
Male	4	4.3	nc	(nc-nc)					
Female	3	3.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Duxbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	14.8	80.8	(41.7-141.2)	Male	22	8.4	260.5	(163.2-394.5)
Female	6	5.4	110.7	(40.4-241.1)	Female	12	6.9	173.5	(89.6-303.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.1	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	5	2.6	188.8	(60.9-440.7)	Female	3	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	8	7.9	100.9	(43.4-198.7)
Female	57	61.7	92.4	(69.9-119.7)	Female	8	7.2	111.5	(48.0-219.8)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	0	2.7	nc	(nc-nc)	Male	2	6.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	3.0	nc	(nc-nc)
Male	28	23.0	121.5	(80.7-175.6)	<u>Ovary</u>				
Female	21	22.7	92.6	(57.3-141.5)	Female	5	6.4	77.8	(25.1-181.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	3.9	nc	(nc-nc)	Male	7	4.4	158.9	(63.6-327.3)
Female	1	1.1	nc	(nc-nc)	Female	2	4.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.2	nc	(nc-nc)	Male	105	63.7	164.9	(134.9-199.6)
Female	2	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	1	3.9	nc	(nc-nc)
Male	6	6.6	90.3	(33.0-196.5)	Female	1	2.4	nc	(nc-nc)
Female	4	4.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.8	nc	(nc-nc)
Male	2	2.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	0.7	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
<u>Leukemia</u>					Female	8	5.6	143.2	(61.6-282.1)
Male	9	4.8	187.6	(85.6-356.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	4.1	nc	(nc-nc)	Female	15	12.5	120.4	(67.3-198.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.1	nc	(nc-nc)	Male	259	206.7	125.3	(110.5-141.6)
Female	1	1.1	nc	(nc-nc)	Female	206	197.8	104.1	(90.4-119.4)
<u>Lung and Bronchus</u>									
Male	26	28.7	90.4	(59.1-132.5)					
Female	29	25.7	113.0	(75.7-162.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# East Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	11.0	63.4	(25.4-130.6)	Male	7	6.6	105.8	(42.4-217.9)
Female	2	4.0	nc	(nc-nc)	Female	8	5.6	142.6	(61.4-280.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.5	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	4	6.2	nc	(nc-nc)
Female	58	46.6	124.3	(94.4-160.7)	Female	6	5.4	110.4	(40.3-240.2)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	3	2.3	nc	(nc-nc)	Male	8	4.8	167.7	(72.2-330.5)
<u>Colon / Rectum</u>					Female	3	2.2	nc	(nc-nc)
Male	23	17.2	134.0	(84.9-201.1)	<u>Ovary</u>				
Female	20	16.2	123.2	(75.2-190.3)	Female	6	4.9	123.7	(45.2-269.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.9	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	5	3.4	147.2	(47.4-343.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.1	nc	(nc-nc)	Male	57	47.3	120.6	(91.4-156.3)
Female	2	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	1	2.9	nc	(nc-nc)
Male	3	5.0	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
Female	4	3.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.1	nc	(nc-nc)
Male	2	2.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	3	0.6	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<u>Leukemia</u>					Female	6	4.9	122.4	(44.7-266.4)
Male	1	3.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	3.1	nc	(nc-nc)	Female	9	9.4	95.9	(43.8-182.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.3	nc	(nc-nc)	Male	159	156.4	101.6	(86.5-118.7)
Female	1	0.8	nc	(nc-nc)	Female	169	149.3	113.2	(96.7-131.6)
<u>Lung and Bronchus</u>									
Male	29	21.6	134.3	(89.9-192.9)					
Female	14	19.4	72.3	(39.5-121.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

## East Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.4	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	10	8.4	119.6	(57.2-219.9)	Female	2	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	1	3.7	nc	(nc-nc)	<u>Ovary</u>				
Female	3	3.1	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.6	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	9	10.0	90.4	(41.3-171.7)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	3	0.6	nc	(nc-nc)
Male	2	1.0	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.8	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.6	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.5	nc	(nc-nc)	Male	33	32.8	100.7	(69.3-141.5)
Female	0	0.2	nc	(nc-nc)	Female	27	27.4	98.4	(64.8-143.2)
<u>Lung and Bronchus</u>									
Male	8	4.7	171.9	(74.0-338.8)					
Female	4	3.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# East Longmeadow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	19.0	94.9	(56.2-150.0)	Male	15	9.5	157.7	(88.2-260.1)
Female	8	7.3	109.9	(47.3-216.7)	Female	7	7.7	91.1	(36.5-187.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.2	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
Female	4	3.0	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	11	9.2	119.0	(59.3-213.0)
Female	88	69.2	127.2	(102.0-156.7)	Female	13	9.1	142.5	(75.8-243.8)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	4	2.8	nc	(nc-nc)	Male	3	6.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	5	3.5	140.9	(45.4-328.9)
Male	14	28.4	49.3	(26.9-82.8)	<u>Ovary</u>				
Female	23	30.4	75.7	(48.0-113.6)	Female	7	7.4	94.5	(37.9-194.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	4.6	nc	(nc-nc)	Male	5	5.4	93.4	(30.1-218.0)
Female	1	1.4	nc	(nc-nc)	Female	6	6.4	93.2	(34.0-202.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.2	nc	(nc-nc)	Male	73	74.6	97.8	(76.7-123.0)
Female	2	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	6	4.8	126.1	(46.0-274.4)
Male	8	7.5	106.7	(46.0-210.3)	Female	3	3.2	nc	(nc-nc)
Female	2	5.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.0	nc	(nc-nc)
Male	5	3.2	157.2	(50.7-366.9)	<u>Thyroid</u>				
Female	2	0.9	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
<u>Leukemia</u>					Female	3	5.6	nc	(nc-nc)
Male	3	5.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	5.1	98.2	(31.7-229.3)	Female	12	13.9	86.4	(44.6-150.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.5	nc	(nc-nc)	Male	215	245.8	87.5	(76.2-100.0)
Female	4	1.4	nc	(nc-nc)	Female	246	239.2	102.8	(90.4-116.5)
<u>Lung and Bronchus</u>									
Male	27	35.8	75.4	(49.6-109.6)					
Female	20	33.7	59.4	(36.3-91.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Eastham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	11.0	127.3	(69.5-213.5)	Male	9	5.0	181.8	(82.9-345.1)
Female	5	3.3	152.4	(49.1-355.6)	Female	6	3.4	179.0	(65.4-389.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.6	nc	(nc-nc)	Male	6	1.5	393.6	(143.7-856.8)
Female	2	1.3	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	4.9	nc	(nc-nc)
Female	38	31.2	121.7	(86.1-167.1)	Female	3	4.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	0	1.2	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	1.6	nc	(nc-nc)
Male	17	16.1	105.3	(61.3-168.6)	<u>Ovary</u>				
Female	20	13.0	153.8	(93.9-237.6)	Female	2	3.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.6	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	64	42.5	150.6	(115.9-192.3)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	1	2.7	nc	(nc-nc)
Male	2	4.0	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
Female	4	2.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.7	nc	(nc-nc)
Male	0	1.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Leukemia</u>					Female	3	2.3	nc	(nc-nc)
Male	3	3.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	2.1	nc	(nc-nc)	Female	9	6.6	136.7	(62.4-259.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.8	nc	(nc-nc)	Male	159	137.2	115.9	(98.6-135.4)
Female	0	0.6	nc	(nc-nc)	Female	118	107.0	110.3	(91.3-132.1)
<u>Lung and Bronchus</u>									
Male	15	20.7	72.5	(40.6-119.6)					
Female	9	16.2	55.7	(25.4-105.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Easthampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	17.1	105.0	(62.2-165.9)	Male	8	9.4	84.8	(36.5-167.2)
Female	7	6.5	108.1	(43.3-222.8)	Female	7	7.9	88.2	(35.3-181.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.3	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
Female	6	3.0	201.2	(73.5-438.0)	Female	1	2.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	11	9.0	122.4	(61.0-219.0)
Female	73	67.5	108.2	(84.8-136.0)	Female	9	8.5	105.7	(48.2-200.6)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	1	3.0	nc	(nc-nc)	Male	10	6.5	152.9	(73.2-281.1)
<u>Colon / Rectum</u>					Female	3	3.4	nc	(nc-nc)
Male	31	26.1	118.8	(80.7-168.6)	<u>Ovary</u>				
Female	30	27.0	111.2	(75.0-158.7)	Female	5	7.1	70.0	(22.6-163.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	4.2	142.2	(51.9-309.4)	Male	10	4.9	203.8	(97.6-374.8)
Female	0	1.3	nc	(nc-nc)	Female	7	5.7	123.1	(49.3-253.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.5	nc	(nc-nc)	Male	55	66.5	82.7	(62.3-107.7)
Female	1	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	4	4.4	nc	(nc-nc)
Male	8	7.1	113.0	(48.6-222.6)	Female	0	2.8	nc	(nc-nc)
Female	3	4.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.6	nc	(nc-nc)
Male	2	2.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.8	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
<u>Leukemia</u>					Female	4	6.4	nc	(nc-nc)
Male	6	5.4	110.9	(40.5-241.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	4.7	nc	(nc-nc)	Female	6	13.4	44.8	(16.3-97.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	3.4	nc	(nc-nc)	Male	232	227.2	102.1	(89.4-116.1)
Female	1	1.3	nc	(nc-nc)	Female	208	226.3	91.9	(79.9-105.3)
<u>Lung and Bronchus</u>									
Male	39	32.3	120.7	(85.8-165.0)					
Female	21	30.8	68.2	(42.2-104.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Easton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	18.6	112.8	(69.8-172.5)	Male	23	11.3	204.1	(129.4-306.3)
Female	6	6.4	94.5	(34.5-205.6)	Female	6	9.4	63.7	(23.3-138.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	4.2	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	3	3.5	nc	(nc-nc)	Female	0	2.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	13	10.5	123.4	(65.6-211.0)
Female	99	78.2	126.7	(102.9-154.2)	Female	4	8.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	10	3.8	265.6	(127.1-488.4)	Male	7	8.3	84.4	(33.8-174.0)
<u>Colon / Rectum</u>					Female	3	3.7	nc	(nc-nc)
Male	24	29.1	82.6	(52.9-122.9)	<u>Ovary</u>				
Female	27	25.8	104.7	(69.0-152.3)	Female	4	8.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	5.0	140.0	(56.1-288.5)	Male	5	5.5	90.3	(29.1-210.7)
Female	1	1.3	nc	(nc-nc)	Female	6	5.4	111.6	(40.8-242.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.0	nc	(nc-nc)	Male	89	81.8	108.8	(87.4-133.9)
Female	3	1.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	4	4.8	nc	(nc-nc)
Male	9	8.6	104.7	(47.8-198.8)	Female	2	2.7	nc	(nc-nc)
Female	2	5.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	3.5	nc	(nc-nc)
Male	1	3.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.9	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
<u>Leukemia</u>					Female	7	8.4	83.5	(33.5-172.1)
Male	5	6.3	78.8	(25.4-183.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	5.0	99.5	(32.1-232.1)	Female	10	15.8	63.4	(30.4-116.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	4.1	nc	(nc-nc)	Male	257	267.1	96.2	(84.8-108.7)
Female	2	1.3	nc	(nc-nc)	Female	245	245.9	99.6	(87.5-112.9)
<u>Lung and Bronchus</u>									
Male	26	36.6	71.0	(46.4-104.1)					
Female	28	31.5	88.8	(59.0-128.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Edgartown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	4.0	nc	(nc-nc)	Male	0	2.4	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	3	1.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.8	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
Female	10	15.7	63.8	(30.5-117.4)	Female	3	1.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	1	0.7	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.8	nc	(nc-nc)
Male	4	6.3	nc	(nc-nc)	<u>Ovary</u>				
Female	10	5.4	183.7	(88.0-337.9)	Female	4	1.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.1	nc	(nc-nc)	Male	4	1.2	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	4	1.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	18	17.6	102.3	(60.6-161.8)
Female	1	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	0	1.0	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.6	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.2	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.5	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.0	nc	(nc-nc)	Female	4	3.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.9	nc	(nc-nc)	Male	55	57.0	96.5	(72.7-125.7)
Female	0	0.3	nc	(nc-nc)	Female	56	50.0	112.0	(84.6-145.5)
<u>Lung and Bronchus</u>									
Male	10	8.0	125.5	(60.1-230.9)					
Female	5	6.8	73.9	(23.8-172.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Egremont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.4	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	4	7.4	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	2	3.6	nc	(nc-nc)	<u>Ovary</u>				
Female	2	2.7	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	9.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	0	0.6	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.6	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	13	30.8	42.3	(22.5-72.3)
Female	0	0.1	nc	(nc-nc)	Female	17	23.9	71.1	(41.4-113.8)
<u>Lung and Bronchus</u>									
Male	2	4.5	nc	(nc-nc)					
Female	2	3.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Erving

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	1.8	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	4	6.1	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.3	nc	(nc-nc)
Male	0	2.7	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	2.3	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	6	7.2	82.9	(30.3-180.5)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.5	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.6	nc	(nc-nc)
Male	2	0.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.4	nc	(nc-nc)	Female	3	1.2	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	20	23.9	83.6	(51.1-129.2)
Female	0	0.1	nc	(nc-nc)	Female	18	20.1	89.7	(53.1-141.7)
<b><u>Lung and Bronchus</u></b>									
Male	3	3.4	nc	(nc-nc)					
Female	3	2.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Essex

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	3.7	135.4	(43.7-316.1)	Male	4	2.1	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	3	1.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.7	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	6	0.6	1028.3	(375.5-2238.3)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	19	13.4	141.8	(85.3-221.5)	Female	1	1.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	0	0.6	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.7	nc	(nc-nc)
Male	4	5.7	nc	(nc-nc)	<u>Ovary</u>				
Female	6	4.9	122.2	(44.6-266.0)	Female	0	1.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.9	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	3	1.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	20	15.4	129.9	(79.3-200.6)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	2	0.9	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.5	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.3	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.9	nc	(nc-nc)	Female	1	2.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.8	nc	(nc-nc)	Male	52	50.5	102.9	(76.8-135.0)
Female	0	0.2	nc	(nc-nc)	Female	58	43.5	133.4	(101.3-172.5)
<u>Lung and Bronchus</u>									
Male	5	7.2	69.3	(22.3-161.6)					
Female	13	5.9	221.1	(117.6-378.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Everett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	49	39.6	123.8	(91.6-163.7)	Male	11	20.9	52.6	(26.2-94.1)
Female	11	15.7	70.1	(34.9-125.4)	Female	15	18.6	80.6	(45.1-132.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	16	7.4	215.7	(123.2-350.3)	Male	6	5.7	105.9	(38.7-230.6)
Female	3	7.1	nc	(nc-nc)	Female	1	5.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	21	20.2	103.9	(64.3-158.8)
Female	133	155.2	85.7	(71.7-101.6)	Female	23	20.3	113.1	(71.7-169.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	7.0	71.7	(23.1-167.2)	Male	18	14.1	127.2	(75.4-201.1)
<b><u>Colon / Rectum</u></b>					Female	12	8.0	150.9	(77.9-263.7)
Male	80	59.4	134.8	(106.8-167.7)	<b><u>Ovary</u></b>				
Female	72	64.7	111.3	(87.1-140.1)	Female	21	16.6	126.2	(78.1-192.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	12	9.6	125.3	(64.7-218.9)	Male	13	11.2	116.5	(62.0-199.3)
Female	3	3.1	nc	(nc-nc)	Female	22	13.7	160.3	(100.4-242.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	3.4	nc	(nc-nc)	Male	142	155.7	91.2	(76.8-107.5)
Female	4	3.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	13	10.0	129.7	(69.0-221.9)
Male	15	15.8	94.9	(53.1-156.6)	Female	10	6.9	145.7	(69.7-267.9)
Female	23	11.3	204.0	(129.3-306.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	6.5	77.1	(24.8-179.9)
Male	6	6.6	90.3	(33.0-196.4)	<b><u>Thyroid</u></b>				
Female	1	2.0	nc	(nc-nc)	Male	2	4.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	18	14.9	120.6	(71.4-190.6)
Male	13	12.4	104.6	(55.7-178.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	13	11.3	114.7	(61.0-196.1)	Female	22	31.3	70.2	(44.0-106.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	7	7.3	95.8	(38.4-197.4)	Male	570	521.4	109.3	(100.5-118.7)
Female	2	3.2	nc	(nc-nc)	Female	548	533.7	102.7	(94.3-111.6)
<b><u>Lung and Bronchus</u></b>									
Male	97	74.7	129.9	(105.4-158.5)					
Female	99	74.1	133.5	(108.5-162.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Fairhaven

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	30	22.2	135.3	(91.3-193.2)	Male	6	10.9	54.9	(20.0-119.5)
Female	6	8.8	68.1	(24.9-148.3)	Female	9	9.1	99.2	(45.3-188.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.7	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
Female	4	3.5	nc	(nc-nc)	Female	2	2.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	12	10.7	112.3	(58.0-196.2)
Female	81	81.0	100.0	(79.4-124.3)	Female	12	11.0	109.5	(56.5-191.2)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	2	3.2	nc	(nc-nc)	Male	6	7.6	78.9	(28.8-171.7)
<u>Colon / Rectum</u>					Female	2	4.2	nc	(nc-nc)
Male	31	33.0	93.8	(63.8-133.2)	<u>Ovary</u>				
Female	32	37.1	86.2	(59.0-121.7)	Female	10	8.8	114.2	(54.7-210.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	5.3	95.1	(30.6-221.9)	Male	1	6.2	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	9	7.8	114.7	(52.3-217.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.4	nc	(nc-nc)	Male	109	84.3	129.4	(106.2-156.1)
Female	1	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	8	5.6	142.9	(61.5-281.7)
Male	13	8.5	152.8	(81.3-261.3)	Female	3	4.0	nc	(nc-nc)
Female	6	6.0	99.6	(36.4-216.8)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.3	nc	(nc-nc)
Male	2	3.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.0	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
<u>Leukemia</u>					Female	5	6.5	77.2	(24.9-180.1)
Male	7	6.5	107.0	(42.9-220.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	6.1	114.6	(45.9-236.1)	Female	14	16.3	85.8	(46.9-144.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.9	nc	(nc-nc)	Male	303	282.1	107.4	(95.7-120.2)
Female	0	1.8	nc	(nc-nc)	Female	267	285.0	93.7	(82.8-105.6)
<u>Lung and Bronchus</u>									
Male	41	41.1	99.7	(71.6-135.3)					
Female	35	40.2	87.1	(60.6-121.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Fall River

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	102	104.1	98.0	(79.9-119.0)	Male	15	52.4	28.6	(16.0-47.2)
Female	51	44.3	115.2	(85.8-151.5)	Female	22	47.0	46.8	(29.3-70.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	13	18.4	70.5	(37.5-120.6)	Male	17	14.8	115.2	(67.1-184.4)
Female	23	18.5	124.4	(78.8-186.7)	Female	10	14.4	69.4	(33.2-127.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	3.1	nc	(nc-nc)	Male	44	51.3	85.8	(62.3-115.2)
Female	329	404.0	81.4	(72.9-90.7)	Female	54	55.7	97.0	(72.8-126.5)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	26	16.8	154.7	(101.1-226.7)	Male	48	35.7	134.3	(99.0-178.0)
<u>Colon / Rectum</u>					Female	20	21.3	93.8	(57.3-144.9)
Male	165	155.3	106.3	(90.7-123.8)	<u>Ovary</u>				
Female	165	185.6	88.9	(75.9-103.6)	Female	39	44.1	88.5	(62.9-121.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	30	24.7	121.6	(82.0-173.6)	Male	34	29.2	116.4	(80.6-162.7)
Female	7	8.8	79.6	(31.9-164.1)	Female	36	39.4	91.5	(64.0-126.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	9	7.9	113.4	(51.7-215.2)	Male	324	396.3	81.7	(73.1-91.2)
Female	6	7.6	78.7	(28.7-171.3)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	33	26.3	125.6	(86.4-176.4)
Male	45	40.2	112.0	(81.7-149.9)	Female	29	19.9	145.6	(97.5-209.1)
Female	32	30.5	105.0	(71.8-148.2)	<u>Testis</u>				
<u>Larynx</u>					Male	4	13.8	nc	(nc-nc)
Male	26	17.0	153.0	(99.9-224.1)	<u>Thyroid</u>				
Female	12	5.2	229.2	(118.3-400.4)	Male	4	10.0	nc	(nc-nc)
<u>Leukemia</u>					Female	34	34.8	97.6	(67.6-136.4)
Male	41	31.9	128.4	(92.1-174.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	28	31.5	89.0	(59.1-128.6)	Female	76	81.6	93.1	(73.4-116.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	26	18.5	140.3	(91.6-205.5)	Male	1364	1336.5	102.1	(96.7-107.6)
Female	11	8.9	124.2	(61.9-222.3)	Female	1296	1437.3	90.2	(85.3-95.2)
<u>Lung and Bronchus</u>									
Male	269	193.4	139.1	(123.0-156.8)					
Female	170	203.5	83.5	(71.5-97.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Falmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	65	54.3	119.8	(92.4-152.6)	Male	44	25.6	172.2	(125.1-231.1)
Female	21	18.7	112.0	(69.3-171.3)	Female	33	19.4	169.8	(116.9-238.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	14	8.3	168.5	(92.1-282.8)	Male	14	7.6	183.3	(100.1-307.5)
Female	9	7.5	120.1	(54.8-228.0)	Female	14	6.1	229.1	(125.1-384.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	5	1.6	308.2	(99.3-719.2)	Male	24	25.1	95.6	(61.2-142.3)
Female	208	179.5	115.9	(100.7-132.8)	Female	26	23.3	111.6	(72.9-163.5)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	8	6.9	115.5	(49.7-227.5)	Male	10	18.2	55.0	(26.3-101.2)
<u>Colon / Rectum</u>					Female	7	9.2	76.1	(30.5-156.7)
Male	85	80.4	105.8	(84.5-130.8)	<u>Ovary</u>				
Female	68	76.0	89.5	(69.5-113.4)	Female	19	19.1	99.4	(59.8-155.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	13.0	69.5	(31.7-131.9)	Male	19	15.2	125.3	(75.4-195.6)
Female	0	3.7	nc	(nc-nc)	Female	21	16.3	129.0	(79.8-197.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.9	nc	(nc-nc)	Male	273	215.2	126.8	(112.2-142.8)
Female	2	2.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	13	13.5	96.3	(51.2-164.7)
Male	21	20.6	101.9	(63.0-155.7)	Female	9	7.9	113.7	(51.9-215.8)
Female	13	13.3	98.1	(52.2-167.7)	<u>Testis</u>				
<u>Larynx</u>					Male	10	4.2	240.9	(115.4-443.1)
Male	13	8.9	145.3	(77.3-248.4)	<u>Thyroid</u>				
Female	4	2.4	nc	(nc-nc)	Male	4	4.4	nc	(nc-nc)
<u>Leukemia</u>					Female	11	13.5	81.2	(40.5-145.3)
Male	17	15.4	110.7	(64.4-177.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	16	12.5	128.0	(73.1-207.9)	Female	32	37.5	85.3	(58.3-120.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	9.5	52.7	(17.0-123.0)	Male	800	691.9	115.6	(107.8-123.9)
Female	1	3.7	nc	(nc-nc)	Female	673	615.2	109.4	(101.3-118.0)
<u>Lung and Bronchus</u>									
Male	97	102.3	94.8	(76.9-115.6)					
Female	106	89.7	118.1	(96.7-142.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Fitchburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	37	40.7	90.9	(64.0-125.3)	Male	13	21.1	61.6	(32.7-105.3)
Female	20	16.3	123.0	(75.1-189.9)	Female	11	18.1	60.7	(30.3-108.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	7.6	nc	(nc-nc)	Male	2	5.8	nc	(nc-nc)
Female	9	7.2	125.4	(57.2-238.1)	Female	1	5.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	18	20.6	87.5	(51.8-138.3)
Female	149	153.3	97.2	(82.2-114.1)	Female	22	20.7	106.2	(66.5-160.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	7	6.6	106.2	(42.6-218.8)	Male	20	14.3	139.4	(85.1-215.3)
<b><u>Colon / Rectum</u></b>					Female	7	8.0	87.4	(35.0-180.1)
Male	57	60.9	93.5	(70.8-121.2)	<b><u>Ovary</u></b>				
Female	66	68.0	97.1	(75.1-123.5)	Female	15	16.6	90.1	(50.4-148.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	11	9.7	113.0	(56.3-202.2)	Male	7	11.5	61.1	(24.5-126.0)
Female	5	3.2	155.0	(50.0-361.7)	Female	9	14.4	62.5	(28.5-118.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	3.4	nc	(nc-nc)	Male	156	156.3	99.8	(84.8-116.8)
Female	3	3.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	9	10.3	87.5	(39.9-166.0)
Male	17	16.0	105.9	(61.7-169.6)	Female	9	7.3	123.1	(56.2-233.7)
Female	10	11.4	87.9	(42.1-161.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	10	6.1	165.0	(79.0-303.4)
Male	8	6.7	118.9	(51.2-234.3)	<b><u>Thyroid</u></b>				
Female	0	2.0	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	16	14.0	114.7	(65.5-186.3)
Male	9	12.8	70.2	(32.0-133.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	8	11.9	66.9	(28.8-131.9)	Female	24	30.7	78.2	(50.1-116.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	9	7.4	120.9	(55.2-229.5)	Male	497	529.4	93.9	(85.8-102.5)
Female	3	3.3	nc	(nc-nc)	Female	484	538.5	89.9	(82.0-98.2)
<b><u>Lung and Bronchus</u></b>									
Male	63	76.1	82.8	(63.6-105.9)					
Female	55	74.9	73.5	(55.4-95.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Florida

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	5	2.8	180.7	(58.2-421.7)	Female	0	0.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.1	nc	(nc-nc)
Male	3	1.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	1.0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
Female	1	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.2	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.3	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.2	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	11	11.2	97.8	(48.8-175.0)
Female	0	0.1	nc	(nc-nc)	Female	14	8.9	156.5	(85.5-262.6)
<b><u>Lung and Bronchus</u></b>									
Male	1	1.6	nc	(nc-nc)					
Female	2	1.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Foxborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	15.9	75.4	(38.9-131.7)	Male	18	9.1	197.1	(116.7-311.5)
Female	9	5.7	157.7	(72.0-299.4)	Female	12	7.5	159.0	(82.1-277.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.3	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	1	2.8	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	10	8.6	116.5	(55.8-214.3)
Female	88	64.6	136.3	(109.3-168.0)	Female	8	7.6	104.6	(45.0-206.1)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	2	3.0	nc	(nc-nc)	Male	7	6.6	105.9	(42.4-218.3)
<u>Colon / Rectum</u>					Female	3	3.1	nc	(nc-nc)
Male	29	24.5	118.4	(79.3-170.1)	<u>Ovary</u>				
Female	28	23.0	121.6	(80.8-175.7)	Female	8	6.7	119.2	(51.3-234.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	4.2	nc	(nc-nc)	Male	3	4.7	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	8	4.9	164.7	(70.9-324.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.4	nc	(nc-nc)	Male	80	68.4	117.0	(92.7-145.6)
Female	2	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	3	4.1	nc	(nc-nc)
Male	9	7.1	127.0	(58.0-241.2)	Female	5	2.4	209.3	(67.5-488.5)
Female	3	4.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	5	2.5	196.2	(63.2-457.8)
Male	1	3.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.8	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
<u>Leukemia</u>					Female	6	6.3	94.6	(34.5-205.9)
Male	7	5.2	134.3	(53.8-276.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	4.3	258.6	(128.9-462.7)	Female	10	13.1	76.2	(36.5-140.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.3	nc	(nc-nc)	Male	242	222.3	108.8	(95.6-123.5)
Female	1	1.2	nc	(nc-nc)	Female	253	208.5	121.4	(106.9-137.3)
<u>Lung and Bronchus</u>									
Male	26	31.2	83.3	(54.4-122.0)					
Female	31	28.1	110.5	(75.0-156.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Framingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	63	66.5	94.7	(72.8-121.2)	Male	40	36.8	108.7	(77.6-148.0)
Female	28	25.3	110.5	(73.4-159.7)	Female	41	31.9	128.5	(92.2-174.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	11	13.1	83.9	(41.8-150.1)	Male	16	9.7	165.1	(94.3-268.2)
Female	8	11.9	67.0	(28.8-132.0)	Female	10	8.2	121.4	(58.1-223.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	2.1	nc	(nc-nc)	Male	37	35.0	105.6	(74.3-145.6)
Female	282	263.7	107.0	(94.8-120.2)	Female	43	33.3	129.2	(93.5-174.0)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	16	12.2	131.4	(75.0-213.3)	Male	26	25.6	101.5	(66.3-148.8)
<u>Colon / Rectum</u>					Female	17	13.3	127.9	(74.4-204.7)
Male	112	101.0	110.9	(91.3-133.4)	<u>Ovary</u>				
Female	115	105.0	109.5	(90.4-131.5)	Female	27	28.1	96.2	(63.4-139.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	12	16.6	72.1	(37.2-126.0)	Male	16	19.1	83.9	(47.9-136.3)
Female	4	5.0	nc	(nc-nc)	Female	25	22.1	113.2	(73.2-167.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	8	6.0	133.0	(57.3-262.1)	Male	230	270.1	85.1	(74.5-96.9)
Female	2	5.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	20	17.1	117.2	(71.6-181.0)
Male	33	27.8	118.6	(81.6-166.6)	Female	13	11.2	115.9	(61.7-198.2)
Female	20	18.5	108.0	(65.9-166.7)	<u>Testis</u>				
<u>Larynx</u>					Male	13	11.4	113.8	(60.5-194.6)
Male	9	11.7	77.3	(35.3-146.7)	<u>Thyroid</u>				
Female	3	3.3	nc	(nc-nc)	Male	10	7.7	129.5	(62.0-238.2)
<u>Leukemia</u>					Female	34	26.4	128.8	(89.2-179.9)
Male	23	21.3	108.0	(68.4-162.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	25	18.8	132.7	(85.8-195.9)	Female	64	53.1	120.5	(92.8-153.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	16	12.9	123.6	(70.6-200.8)	Male	857	898.4	95.4	(89.1-102.0)
Female	6	5.1	116.6	(42.6-253.8)	Female	947	887.7	106.7	(100.0-113.7)
<u>Lung and Bronchus</u>									
Male	103	126.4	81.5	(66.5-98.8)					
Female	106	119.2	89.0	(72.8-107.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Franklin

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	20.6	102.0	(63.1-155.9)	Male	13	13.2	98.9	(52.6-169.1)
Female	4	7.5	nc	(nc-nc)	Female	17	11.6	146.7	(85.4-235.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.1	116.8	(42.6-254.2)	Male	5	3.1	159.7	(51.5-372.7)
Female	3	4.4	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	9	12.2	73.9	(33.7-140.3)
Female	105	92.6	113.4	(92.8-137.3)	Female	10	10.6	94.3	(45.1-173.4)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	4	4.9	nc	(nc-nc)	Male	9	9.2	98.0	(44.7-186.0)
<u>Colon / Rectum</u>					Female	4	4.4	nc	(nc-nc)
Male	37	32.2	115.0	(81.0-158.5)	<u>Ovary</u>				
Female	31	30.5	101.6	(69.0-144.2)	Female	12	9.5	125.8	(64.9-219.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	5.5	91.4	(29.4-213.2)	Male	5	6.1	82.2	(26.5-191.7)
Female	3	1.5	nc	(nc-nc)	Female	6	6.3	94.6	(34.5-205.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.4	nc	(nc-nc)	Male	99	87.4	113.3	(92.0-137.9)
Female	3	2.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	5	5.4	92.3	(29.7-215.4)
Male	9	9.7	92.4	(42.2-175.5)	Female	2	3.2	nc	(nc-nc)
Female	3	6.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	6	4.8	124.8	(45.6-271.6)
Male	3	3.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.1	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
<u>Leukemia</u>					Female	8	10.8	73.9	(31.8-145.5)
Male	5	7.5	66.4	(21.4-154.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	6.3	126.4	(54.4-249.0)	Female	15	18.0	83.4	(46.7-137.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	4.6	nc	(nc-nc)	Male	298	297.0	100.4	(89.3-112.4)
Female	2	1.5	nc	(nc-nc)	Female	293	292.4	100.2	(89.1-112.4)
<u>Lung and Bronchus</u>									
Male	41	40.3	101.8	(73.0-138.1)					
Female	28	36.6	76.4	(50.8-110.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;